Joint revision procedures place a tremendous economic burden on the healthcare system. Current figures from the Norway show that the cost of revision surgeries exceeded NOK 2.5 Billion in 2012 [1]. Data from The Norwegian Arthroplasty Register (NAR) demonstrate that 14.3% of all hip and 8.5% of all knee joint replacement surgeries are revision surgeries [2]. In UK 2012 12% of all hip joint and 6.5% of all knee joint replacement surgeries are revisions [3].

 Current figures from the US show that revision procedures account for approximately 19% and 8% of all total hip and knee replacements, respectively that is reimbursed by Medicare  [4]. Medicare reimbursements for revision of total joint replacements have been projected to exceed $8.5 billion by 2015.

 As a result of improved surgical techniques and total joint artroplasty (TJA)  becoming a routine surgery, the age of the patients receiving TJA is steadily decreasing and so is the threshold level of arthritis necessitating the procedure.